News | February 21, 2020
In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges...
News | February 6, 2020
FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the...
With a range of OTC skin care products and a growing presence in aesthetics, Crown Laboratories—maker of SkinPen—is dedicated to patient care. President & CEO Jeff Bedard speaks with host Steve Dayan, MD.
The architecture of cellulite leads to its unique appearance and complex treatment. Advancements in device technology allow for better results than ever for dimpling, sagging, and other features of the disease, say Mathew Avram, MD and Jeremy Green, MD. Combination approaches may yield best outcomes.
From Baby Botox to Daddy Do-Overs, the Aesthetic Society Predicts the Hottest Trends for 2020
Ground Up NYC
Building a "tech-forward" practice and going paperless were important goals for Manhattan's Melissa Kanchanapoomi Levin, MD. Hear...
Melissa Kanchanapoomi Levin, MD
Dr. Susan Weinkle Honored with Outstanding Educator & Mentor in Dermatology Award at ODAC
Credentials Over Cost: AAFPRS Issues Warning to Consumers about Discount Cosmetic Treatments
Revance enters an exclusive distribution deal with Teoxane to bring RHA line of fillers to US Market, Allergan revamps its customer loyalty rewards...
Revance Enters Exclusive Distribution Deal with Teoxane SA for Dermal Fillers
With a range of OTC skin care products and a growing presence in aesthetics, Crown Laboratories—maker of SkinPen—is dedicated to patient...
Steve Dayan, MD; and Jeff Bedard
The architecture of cellulite leads to its unique appearance and complex treatment. Advancements in device technology allow for better results than...
Mathew Avram, MD; and Jeremy B. Green, MD
Revance Therapeutics long-acting neuromodulator is now one step closer to FDA approval, Dr. Joel L. Cohen hosts coverage of Cosmetic Surgery Forum,...